Georg Jaeschke
Overview
Explore the profile of Georg Jaeschke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
898
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mesch S, Shannon J, Miller D, MacLeod A, Bouche L, Johnston H, et al.
J Med Chem
. 2024 Nov;
67(23):20911-20932.
PMID: 39585325
Aberrant activation of NLRP3 due to persistent tissue damage, misfolded proteins or crystal deposits has been linked to multiple chronic inflammatory disorders such as cryopyrin-associated periodic syndrome (CAPS), neurodegenerative diseases,...
2.
Obst-Sander U, Ricci A, Kuhn B, Friess T, Koldewey P, Kuglstatter A, et al.
J Med Chem
. 2022 Sep;
65(19):13052-13073.
PMID: 36178776
Addressing resistance to third-generation EGFR TKIs such as osimertinib via the EGFR mutation remains a highly unmet need in EGFR-driven non-small-cell lung cancer (NSCLC). Herein, we present the discovery of...
3.
Heinig K, Sladojevich F, Schaffland J, Jaeschke G, Ross A, Koldewey P, et al.
Pharm Res
. 2022 Mar;
39(4):653-667.
PMID: 35338426
Purpose: Exploration of the chemical, analytical and pharmacokinetic properties of the API, RO7304898, an allosteric EGFR inhibitor, intended to be developed as a mixture of two rapidly interconverting diastereoisomers with...
4.
5.
Kelly E, Schaeffer S, Dhamne S, Lipton J, Lindemann L, Honer M, et al.
Neuropsychopharmacology
. 2017 Dec;
43(6):1457-1465.
PMID: 29206810
Drugs targeting metabotropic glutamate receptor 5 (mGluR5) have therapeutic potential in autism spectrum disorders (ASD), including tuberous sclerosis complex (TSC). The question whether inhibition or potentiation of mGluR5 could be...
6.
Sturm S, Delporte M, Hadi S, Schobel S, Lindemann L, Weikert R, et al.
Br J Clin Pharmacol
. 2017 Nov;
84(3):445-455.
PMID: 29096426
Aim: The objectives of this first-in-human study were to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, and maximum tolerated dose (MTD) of single ascending oral doses of RG7342, a...
7.
Peterlik D, Stangl C, Bauer A, Bludau A, Keller J, Grabski D, et al.
Brain Behav Immun
. 2016 Aug;
59:79-92.
PMID: 27524668
Etiology and pharmacotherapy of stress-related psychiatric conditions and somatoform disorders are areas of high unmet medical need. Stressors holding chronic plus psychosocial components thereby bear the highest health risk. Although...
8.
Lindemann L, Porter R, Scharf S, Kuennecke B, Bruns A, von Kienlin M, et al.
J Pharmacol Exp Ther
. 2015 Feb;
353(1):213-33.
PMID: 25665805
Major depressive disorder (MDD) is a serious public health burden and a leading cause of disability. Its pharmacotherapy is currently limited to modulators of monoamine neurotransmitters and second-generation antipsychotics. Recently,...
9.
Contribution of mGluR5 to pathophysiology in a mouse model of human chromosome 16p11.2 microdeletion
Tian D, Stoppel L, Heynen A, Lindemann L, Jaeschke G, Mills A, et al.
Nat Neurosci
. 2015 Jan;
18(2):182-4.
PMID: 25581360
Human chromosome 16p11.2 microdeletion is the most common gene copy number variation in autism, but the synaptic pathophysiology caused by this mutation is largely unknown. Using a mouse with the...
10.
Jaeschke G, Kolczewski S, Spooren W, Vieira E, Bitter-Stoll N, Boissin P, et al.
J Med Chem
. 2015 Jan;
58(3):1358-71.
PMID: 25565255
Negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu5) have potential for the treatment of psychiatric diseases including depression, fragile X syndrome (FXS), anxiety, obsessive-compulsive disorders, and levodopa induced...